Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanobiotix S.A. (NANO.PA)
EUR34.98
-1.22 (-3.37%)
FR PAR Healthcare Biotechnology
Address
60 rue de Wattignies 75012
Paris, IDF, FR
Paris, IDF, FR
CEO
Laurent Levy
Website
nanobiotix.com
IPO
2012-10-29
ISIN FR0011341205
Also trades on
Euronext Paris · NANO.PA (EUR)
London Stock Exchange · 0QAV.L (EUR)
NASDAQ Global Select · NBTX (USD)
Other OTC · NNBXF (USD)
Description
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR34.98
-1.22 (-3.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
226.7K
Beta
0.59
Float Shares
48.43M
Free Float %
95.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.12% | -12.13% | +18.52% | +31.94% | +96.08% | +74.56% | +820.00% | +671.01% | +133.79% | +78.03% | +449.03% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
34.98
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.45
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-355.3% Q4'25: -90.9% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+64.6% ★ Q4'25: -33.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-89.1% Q4'25: -546.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-45.8% Q4'25: -478.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +137.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.3% ★ Q4'25: +22.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.90× Q4'25: -1.81× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 3 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.02M
est: 1.57M (+155.9%)
|
5.42M
est: 4.58M (+18.4%)
|
3.72M
est: 10.07M (-63.0%)
|
3.48M
est: 3.35M (+3.9%)
|
68.0K
est: 68.0K (+0.0%)
|
50.0K
est: 50.0K (+0.0%)
|
10.0K
est: 6.82M (-99.9%)
|
4.78M
est: 2.66M (+79.8%)
|
30.06M
est: 42.20M (-28.8%)
|
-11.61M
est: 19.79M (-158.7%)
|
29.64M
est: 40.08M (-26.0%)
|
34.72M
7.92M – 62.23M
-13.4% YoY
|
58.26M
2.56M – 133.25M
+67.8% YoY
|
95.56M
91.88M – 99.23M
+64.0% YoY
|
98.45M
12.41M – 203.46M
+3.0% YoY
|
105.72M
13.33M – 218.48M
+7.4% YoY
|
| EBITDA |
-16.69M
est: -941.6K (-1,672.1%)
|
-21.37M
est: -2.75M (-678.1%)
|
-24.81M
est: -6.04M (-310.8%)
|
-29.45M
est: -2.01M (-1,365.1%)
|
-45.01M
est: -40.8K (-110,223.5%)
|
-31.49M
est: -30.0K (-104,880.0%)
|
-45.61M
est: -4.09M (-1,015.2%)
|
-53.79M
est: -1.59M (-3,273.8%)
|
-30.09M
est: -20.32M (-48.1%)
|
-61.62M
est: -9.53M (-546.9%)
|
-12.07M
est: -19.29M (+37.5%)
|
-16.71M
-29.96M – -3.81M
+13.4% YoY
|
-28.05M
-64.15M – -1.23M
-67.8% YoY
|
-46.00M
-47.77M – -44.23M
-64.0% YoY
|
-47.40M
-97.95M – -5.97M
-3.0% YoY
|
-50.90M
-105.18M – -6.42M
-7.4% YoY
|
| EBIT |
-17.14M
est: -941.6K (-1,720.6%)
|
-21.85M
est: -2.75M (-695.7%)
|
-25.27M
est: -6.04M (-318.3%)
|
-30.07M
est: -2.01M (-1,395.9%)
|
-46.12M
est: -40.8K (-112,934.3%)
|
-30.50M
est: -30.0K (-101,563.3%)
|
-47.17M
est: -4.09M (-1,053.3%)
|
-55.29M
est: -1.59M (-3,367.9%)
|
-31.60M
est: -20.74M (-52.3%)
|
-63.25M
est: -9.73M (-550.3%)
|
-13.56M
est: -19.70M (+31.1%)
|
-17.06M
-30.59M – -3.89M
+13.4% YoY
|
-28.64M
-65.49M – -1.26M
-67.8% YoY
|
-46.97M
-48.77M – -45.16M
-64.0% YoY
|
-48.39M
-100.00M – -6.10M
-3.0% YoY
|
-51.96M
-107.38M – -6.55M
-7.4% YoY
|
| Net Income |
-17.00M
est: -53.41M (+68.2%)
|
-21.88M
est: -56.06M (+61.0%)
|
-26.14M
est: -51.28M (+49.0%)
|
-30.35M
est: -62.59M (+51.5%)
|
-50.92M
est: -95.67M (+46.8%)
|
-33.59M
est: -65.56M (+48.8%)
|
-47.00M
est: -82.23M (+42.8%)
|
-57.04M
est: -58.78M (+3.0%)
|
-39.70M
est: -33.47M (-18.6%)
|
-68.13M
est: -51.64M (-31.9%)
|
-23.96M
est: -23.96M (+0.0%)
|
-9.97M
-27.00M – 9.49M
+58.4% YoY
|
4.08M
-10.72M – 7.72M
+140.9% YoY
|
28.56M
-29.57M – 83.59M
+600.8% YoY
|
27.47M
-3.74M – 65.57M
-3.8% YoY
|
14.46M
-1.97M – 34.52M
-47.4% YoY
|
| SGA |
7.25M
est: 686.97M (-98.9%)
|
10.36M
est: 2.00B (-99.5%)
|
11.26M
est: 4.41B (-99.7%)
|
12.65M
est: 1.47B (-99.1%)
|
18.64M
est: 29.77M (-37.4%)
|
14.22M
est: 21.89M (-35.0%)
|
19.02M
est: 2.98B (-99.4%)
|
17.48M
est: 1.16B (-98.5%)
|
21.66M
est: 16.08B (-99.9%)
|
20.06M
est: 7.54B (-99.7%)
|
20.22M
est: 15.27B (-99.9%)
|
13.23B
3.02B – 23.71B
-13.4% YoY
|
22.20B
977.18M – 50.77B
+67.8% YoY
|
36.41B
35.01B – 37.81B
+64.0% YoY
|
37.51B
4.73B – 77.52B
+3.0% YoY
|
40.28B
5.08B – 83.25B
+7.4% YoY
|
| EPS |
-1.20
est: -1.13 (-6.2%)
|
-1.43
est: -1.19 (-20.6%)
|
-1.50
est: -1.09 (-38.2%)
|
-1.55
est: -1.32 (-17.0%)
|
-2.35
est: -2.02 (-16.1%)
|
-1.38
est: -1.39 (+0.5%)
|
-1.35
est: -1.74 (+22.4%)
|
-1.64
est: -1.44 (-13.7%)
|
-1.08
est: -0.78 (-38.6%)
|
-1.44
est: -1.02 (-41.0%)
|
-0.51
est: -0.17 (-198.1%)
|
-0.19
-0.57 – 0.20
-10.6% YoY
|
-0.05
-0.23 – 0.16
+71.6% YoY
|
0.49
-0.62 – 1.76
+1,007.9% YoY
|
0.58
-0.08 – 1.38
+18.8% YoY
|
0.31
-0.04 – 0.73
-47.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-89.47M
OE per share TTM
-1.89
Owner's Yield
-5.54%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 47 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.21% | 2.21M | 0.58% |
| 2 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.20% | 1.51M | 0.33% |
| 3 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.15% | 1.70M | 0.40% |
| 4 | iShares Ageing Population UCITS ETF AGED.L | 0.12% | 1.03M | 0.40% |
| 5 | iShares International Small-Cap Equity Factor ETF ISCF | 0.11% | 686.7K | 0.24% |
| 6 | iShares MSCI Europe Small-Cap ETF IEUS | 0.08% | 144.5K | 0.41% |
| 7 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.08% | 2.57M | 0.30% |
| 8 | T. Rowe Price Innovation Leaders ETF TNXT | 0.05% | 9.8K | 0.49% |
| 9 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.04% | 80.1K | 0.83% |
| 10 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.04% | 4.83M | 0.40% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-139.8K
Shares Outstanding
50.60M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | 845.0K | male |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 603.2K | — |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 600.2K | male |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | 414.4K | female |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | — | — |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations | — | female |
| Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | — | female |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | — | male |
| Earl J. Bergey | Co-Founder | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NANO.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
